

Emilio Perucca

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1774469/emilio-perucca-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

279
papers

22,067
citations

66
h-index

145
g-index

324
ext. papers

26,400
ext. citations

6.9
avg, IF

7.21
L-index

#	Paper	IF	Citations
279	Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?. <i>CNS Drugs</i> , 2022 , 36, 113	6.7	1
278	International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions.. <i>Epilepsia</i> , 2022 ,	6.4	12
277	Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions.. <i>Epilepsia</i> , 2022 ,	6.4	4
276	ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions.. <i>Epilepsia</i> , 2022 ,	6.4	15
275	The 50th anniversary of the Italian League against epilepsy (Lega Italiana Contro l'Epilessia). <i>Epilepsy and Behavior Reports</i> , 2022 , 19, 100553	1.3	
274	Web-based decision support system for patient-tailored selection of antiseizure medication in adolescents and adults: An external validation study. <i>European Journal of Neurology</i> , 2021 , 29, 382	6	1
273	The EpiPick algorithm to select appropriate antiseizure medications in patients with epilepsy: Validation studies and updates. <i>Epilepsia</i> , 2021 ,	6.4	0
272	Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements. <i>BMC Neurology</i> , 2021 , 21, 410	3.1	1
271	Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. <i>Neuropharmacology</i> , 2021 , 185, 108442	5.5	18
270	New paradigms for the treatment of pediatric monogenic epilepsies: Progressing toward precision medicine. <i>Epilepsy and Behavior</i> , 2021 , 107961	3.2	1
269	Pediatric adverse reactions to antiseizure medications - An analysis of data from the Italian spontaneous reporting system (2001-2019). <i>Epilepsy and Behavior</i> , 2021 , 119, 107989	3.2	2
268	Basal Ganglia Dysmorphism in Patients With Aicardi Syndrome. <i>Neurology</i> , 2021 , 96, e1319-e1333	6.5	3
267	Optimal choice of antiseizure medication: Agreement among experts and validation of a web-based decision support application. <i>Epilepsia</i> , 2021 , 62, 220-227	6.4	7
266	FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force. <i>Epilepsia Open</i> , 2021 , 6, 45-48	4	11
265	The initial impact of the SARS-CoV-2 pandemic on epilepsy research. <i>Epilepsia Open</i> , 2021 , 6, 255-265	4	2
264	A web-based algorithm to rapidly classify seizures for the purpose of drug selection. <i>Epilepsia</i> , 2021 , 62, 2474-2484	6.4	2
263	Epilepsy care during the COVID-19 pandemic. <i>Epilepsia</i> , 2021 , 62, 2322-2332	6.4	13

262	Selection of antiseizure medications for first add-on use: A consensus paper. <i>Epilepsy and Behavior</i> , 2021 , 122, 108087	3.2	2
261	Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know. <i>Pharmacology & Therapeutics</i> , 2021 , 226, 107866	13.9	4
260	Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe. <i>Epilepsia</i> , 2021 , 62, 285-302	6.4	1
259	Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. <i>Epilepsia</i> , 2020 , 61, 1082-1089	6.4	28
258	Relationship between saliva and plasma rufinamide concentrations in patients with epilepsy. <i>Epilepsia</i> , 2020 , 61, e79-e84	6.4	0
257	Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. <i>CNS Drugs</i> , 2020 , 34, 795-800	6.7	29
256	Antiepileptic Drug Teratogenicity and De Novo Genetic Variation Load. <i>Annals of Neurology</i> , 2020 , 87, 897-906	9.4	5
255	Does screening for adverse effects improve health outcomes in epilepsy? A randomized trial. <i>Neurology</i> , 2020 , 95, e239-e246	6.5	4
254	Response: Cannabidiol antiseizure activity and its interactions with clobazam: "It's dīvu all over again" Yogi Berra. <i>Epilepsia</i> , 2020 , 61, 1793-1794	6.4	
253	Time to Start Calling Things by Their Own Names? The Case for Antiseizure Medicines. <i>Epilepsy Currents</i> , 2020 , 20, 69-72	1.3	12
252	30 years of second-generation antiseizure medications: impact and future perspectives. <i>Lancet Neurology</i> , 2020 , 19, 544-556	24.1	48
251	Keeping people with epilepsy safe during the COVID-19 pandemic. <i>Neurology</i> , 2020 , 94, 1032-1037	6.5	91
250	Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review. <i>Epilepsy and Behavior</i> , 2020 , 103, 106861	3.2	3
249	Determination of Perampanel in Dried Plasma Spots: Applicability to Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 309-314	3.2	3
248	Corticosteroids versus clobazam in epileptic encephalopathy with ESES: a European multicentre randomised controlled clinical trial (RESCUE ESES*). <i>Trials</i> , 2020 , 21, 957	2.8	3
247	Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development. <i>Epilepsia</i> , 2020 , 61, 2365-2385	6.4	18
246	A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy. <i>Epilepsia</i> , 2020 , 61, 1668-1677	6.4	11
245	The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 1493-1500	6.2	9

244	Declining malformation rates with changed antiepileptic drug prescribing: An observational study. <i>Neurology</i> , 2019 , 93, e831-e840	6.5	34
243	Neurovascular Drug Biotransformation Machinery in Focal Human Epilepsies: Brain CYP3A4 Correlates with Seizure Frequency and Antiepileptic Drug Therapy. <i>Molecular Neurobiology</i> , 2019 , 56, 8392-8407	6.2	10
242	2017 International League Against Epilepsy classifications of seizures and epilepsy are steps in the right direction. <i>Epilepsia</i> , 2019 , 60, 1040-1044	6.4	9
241	Seizure-alerting behavior in dogs owned by people experiencing seizures. <i>Epilepsy and Behavior</i> , 2019 , 94, 104-111	3.2	10
240	Identifying mutations in epilepsy genes: Impact on treatment selection. <i>Epilepsy Research</i> , 2019 , 152, 18-30	3	53
239	Low risk pragmatic trials do not always require participants' informed consent. <i>BMJ, The</i> , 2019 , 364, l10929	3.9	17
238	Validated outcome of treatment changes according to International League Against Epilepsy criteria in adults with drug-resistant focal epilepsy. <i>Epilepsia</i> , 2019 , 60, 1114-1123	6.4	9
237	Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. <i>Drugs</i> , 2019 , 79, 1435-1454	12.1	55
236	Classification as autonomic versus sensory seizures. <i>Epilepsia</i> , 2019 , 60, 2003-2005	6.4	3
235	Novel therapies for epilepsy in the pipeline. <i>Epilepsy and Behavior</i> , 2019 , 97, 282-290	3.2	16
234	Novel study design to assess the efficacy and tolerability of antiseizure medications for focal-onset seizures in infants and young children: A consensus document from the regulatory task force and the pediatric commission of the International League against Epilepsy (ILAE), in collaboration with the Pediatric Epilepsy Research Consortium (PERC). <i>Epilepsia Open</i> , 2019 , 4, 537-543	4	7
233	Antiepileptic drugs: evolution of our knowledge and changes in drug trials 2019 , 21, 319-329		8
232	Teratogenicity of antiepileptic drugs. <i>Current Opinion in Neurology</i> , 2019 , 32, 246-252	7.1	51
231	Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy?. <i>Epilepsia</i> , 2019 , 60, 175-183	6.4	7
230	Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. <i>Lancet Neurology, The</i> , 2018 , 17, 530-538	24.1	202
229	Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307. <i>Epilepsia</i> , 2018 , 59, 866-876	6.4	42
228	EURAP registry: inadequate monitoring of prescribed drugs in pregnancy - Authors' reply. <i>Lancet Neurology, The</i> , 2018 , 17, 741-742	24.1	2
227	No Evidence of a Causal Role of Antiepileptic Drug Treatment with Regard to the Development of Dementia. <i>Journal of the American Geriatrics Society</i> , 2018 , 66, 1850-1852	5.6	4

226	Advocacy for children with epilepsy: Leveraging the WHA resolution. Advocacy Task Force, Commission of Pediatrics, International League Against Epilepsy. <i>Epilepsia Open</i> , 2018 , 3, 167-174	4	2
225	A simple and rapid HPLC-UV method for the determination of retigabine in human plasma. <i>Biomedical Chromatography</i> , 2018 , 32, e4168	1.7	4
224	ILAE-Klassifikation der Epilepsien: Positionspapier der ILAE-Kommission für Klassifikation und Terminologie. <i>Zeitschrift Fur Epileptologie</i> , 2018 , 31, 296-306	0.1	17
223	From clinical trials of antiepileptic drugs to treatment. <i>Epilepsia Open</i> , 2018 , 3, 220-230	4	24
222	Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development. <i>Epilepsia</i> , 2018 , 59, 1811-1841	6.4	89
221	Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development. <i>Epilepsia</i> , 2018 , 59, 1842-1866	6.4	32
220	Drug interactions with carbamazepine: An ever expanding list?. <i>Epilepsy Research</i> , 2018 , 147, 119-120	3	3
219	No proof of a causal relationship between antiepileptic drug treatment and incidence of dementia. Comment on: Use of antiepileptic drugs and dementia risk-An analysis of Finnish health register and German health insurance data. <i>Epilepsia</i> , 2018 , 59, 1303-1306	6.4	4
218	Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). <i>Epilepsia</i> , 2017 , 58, 181-221	6.4	78
217	ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. <i>Epilepsia</i> , 2017 , 58, 512-521	6.4	2084
216	Maternal and fetal outcomes associated with vagus nerve stimulation during pregnancy. <i>Epilepsy Research</i> , 2017 , 137, 159-162	3	13
215	Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?. <i>Journal of Epilepsy Research</i> , 2017 , 7, 61-76	1.8	125
214	A Tribute to Steve White. <i>Neurochemical Research</i> , 2017 , 42, 1867-1868	4.6	1
213	How long for epilepsy remission in the ILAE definition?. <i>Epilepsia</i> , 2017 , 58, 1486-1487	6.4	3
212	Not all that glitters is gold: A guide to the critical interpretation of drug trials in epilepsy. <i>Epilepsia Open</i> , 2016 , 1, 9-21	4	20
211	Challenges in the clinical development of new antiepileptic drugs. <i>Pharmacological Research</i> , 2016 , 103, 95-104	10.2	50
210	Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. <i>Lancet Neurology</i> , 2016 , 15, 210-218	24.1	123
209	The current state of epilepsy guidelines: A systematic review. <i>Epilepsia</i> , 2016 , 57, 13-23	6.4	39

208	The safety of generic substitution in epilepsy. <i>Lancet Neurology, The</i> , 2016 , 15, 344-5	24.1	3
207	Antiepileptic drug use and epileptic seizures in nursing home residents in the Province of Pavia, Italy: A reappraisal 12 years after a first survey. <i>Epilepsy Research</i> , 2016 , 119, 41-8	3	9
206	Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP. <i>Epilepsia</i> , 2016 , 57, e173-7	6.4	43
205	An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2016 , 43, 685-9	3	3
204	Epilepsy, seizures, physical exercise, and sports: A report from the ILAE Task Force on Sports and Epilepsy. <i>Epilepsia</i> , 2016 , 57, 6-12	6.4	102
203	Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. <i>Neurology</i> , 2015 , 85, 866-72	6.5	95
202	CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 1269-79	5.5	35
201	Antiepileptic drugs and intrauterine death: A prospective observational study from EURAP. <i>Neurology</i> , 2015 , 85, 580-8	6.5	66
200	Commentary: why an international epilepsy day?. <i>Epilepsia</i> , 2015 , 56, 170-1	6.4	2
199	The pharmacogenomics of epilepsy. <i>Expert Review of Neurotherapeutics</i> , 2015 , 15, 1161-70	4.3	28
198	Is a separate monotherapy indication warranted for antiepileptic drugs?. <i>Lancet Neurology, The</i> , 2015 , 14, 1229-40	24.1	30
197	Epilepsy: new advances. <i>Lancet, The</i> , 2015 , 385, 884-98	40	492
196	Brivaracetam 2015 , 418-430		2
195	Pharmacokinetic Optimization of Therapy 2015 , 124-138		
194	General Principles of Medical Management 2015 , 110-123		
193	Developing clinical practice guidelines for epilepsy: A report from the ILAE Epilepsy Guidelines Working Group. <i>Epilepsia</i> , 2015 , 56, 1859-69	6.4	17
192	A prospective study of direct medical costs in a large cohort of consecutively enrolled patients with refractory epilepsy in Italy. <i>Epilepsia</i> , 2015 , 56, 1162-73	6.4	36
191	Availability of antiepileptic drugs across Europe. <i>Epilepsia</i> , 2015 , 56, e191-7	6.4	9

190	From global campaign to global commitment: The World Health Assembly's Resolution on epilepsy. <i>Epilepsia</i> , 2015 , 56, 1651-7	6.4	32
189	Epilepsy priorities in Europe: A report of the ILAE-IBE Epilepsy Advocacy Europe Task Force. <i>Epilepsia</i> , 2015 , 56, 1687-95	6.4	64
188	Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study. <i>Epilepsia</i> , 2015 , 56, 439-49	6.4	19
187	Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). <i>Epilepsy Research</i> , 2015 , 111, 85-141	3	143
186	ILAE official report: a practical clinical definition of epilepsy. <i>Epilepsia</i> , 2014 , 55, 475-82	6.4	2408
185	Gender issues in antiepileptic drug treatment. <i>Neurobiology of Disease</i> , 2014 , 72 Pt B, 217-23	7.5	21
184	Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. <i>Epileptic Disorders</i> , 2014 , 16, 409-31	1.9	151
183	Off-label prescribing of antiepileptic drugs in pharmaco-resistant epilepsy: a cross-sectional drug utilization study of tertiary care centers in Italy. <i>CNS Drugs</i> , 2014 , 28, 939-49	6.7	21
182	Commentary: Epilepsy is a Global Problem. <i>Epilepsia</i> , 2014 , 55, 1326-8	6.4	11
181	The long-term effect of vagus nerve stimulation on quality of life in patients with pharmaco-resistant focal epilepsy: the PuLSE (Open Prospective Randomized Long-term Effectiveness) trial. <i>Epilepsia</i> , 2014 , 55, 893-900	6.4	117
180	The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study. <i>Epilepsy Research</i> , 2013 , 103, 245-53	3	13
179	Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 627-45	6.2	75
178	Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). <i>Epilepsy Research</i> , 2013 , 103, 2-30	3	171
177	Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. <i>Epilepsia</i> , 2013 , 54, 551-63	6.4	467
176	Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation. <i>Expert Review of Neurotherapeutics</i> , 2013 , 13, 615-25	4.3	27
175	Optimizing antiepileptic drug treatment in tumoral epilepsy. <i>Epilepsia</i> , 2013 , 54 Suppl 9, 97-104	6.4	61
174	Identification of new epilepsy treatments: issues in preclinical methodology. <i>Epilepsia</i> , 2012 , 53, 571-82	6.4	171
173	What clinical trial designs have been used to test antiepileptic drugs and do we need to change them?. <i>Epileptic Disorders</i> , 2012 , 14, 124-31	1.9	28

172	Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. <i>Epilepsia</i> , 2012 , 53, 207-14	6.4	31
171	Novel medications for epilepsy. <i>Drugs</i> , 2011 , 71, 2151-78	12.1	41
170	Antiepileptic drug therapy: does mechanism of action matter?. <i>Epilepsy and Behavior</i> , 2011 , 21, 331-41	3.2	101
169	Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. <i>Analytical and Bioanalytical Chemistry</i> , 2011 , 401, 1013-21	4.4	27
168	New and forthcoming anti-epileptic drugs. <i>Current Opinion in Neurology</i> , 2011 , 24, 159-64	7.1	19
167	Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. <i>Epilepsia</i> , 2011 , 52, 219-33	6.4	113
166	A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. <i>Epilepsia</i> , 2011 , 52, 802-9	6.4	49
165	A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. <i>Epilepsia</i> , 2011 , 52, e40-4	6.4	41
164	Determinants of health-related quality of life in pharmaco-resistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. <i>Epilepsia</i> , 2011 , 52, 2181-91	6.4	182
163	The pharmacological treatment of epilepsy in adults. <i>Lancet Neurology, The</i> , 2011 , 10, 446-56	24.1	209
162	Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. <i>Lancet Neurology, The</i> , 2011 , 10, 609-17	24.1	546
161	Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy. <i>Epilepsy Research</i> , 2011 , 94, 117-20	3	18
160	A young woman with recurring seizures. <i>Neurosciences</i> , 2011 , 16, 292-4	0.1	
159	Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i> , 2010 , 51, 1069-77	6.4	2311
158	When the past challenges the present: are older antiepileptic drugs still the best choice in childhood absence epilepsy?. <i>Lancet Neurology, The</i> , 2010 , 9, 457-9	24.1	5
157	Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. <i>Epilepsy Research</i> , 2010 , 91, 273-82	3	42
156	Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). <i>Epilepsy Research</i> , 2010 , 92, 89-124	3	122
155	Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy. <i>Epilepsia</i> , 2010 , 51, 921-5	6.4	29

154	Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. <i>Epilepsia</i> , 2010 , 51, 797-804	6.4	129
153	When clinical trials make history: demonstrating efficacy of new antiepileptic drugs as monotherapy. <i>Epilepsia</i> , 2010 , 51, 1933-5	6.4	16
152	Epilepsy: seizures, syndromes, and survival. <i>Lancet Neurology</i> , 2009 , 8, 10-2	24.1	4
151	Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. <i>Lancet Neurology</i> , 2009 , 8, 82-93	24.1	329
150	Extended-release formulations of antiepileptic drugs: rationale and comparative value. <i>Epilepsy Currents</i> , 2009 , 9, 153-7	1.3	37
149	Italian consensus conference on epilepsy and pregnancy, labor and puerperium. <i>Epilepsia</i> , 2009 , 50 Suppl 1, 7-23	6.4	25
148	Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. <i>Epilepsia</i> , 2009 , 50, 1841-9	6.4	45
147	Rapid onset of seizure suppression with pregabalin adjunctive treatment in patients with partial seizures. <i>Epilepsia</i> , 2009 , 50, 1891-8	6.4	8
146	What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. <i>Epilepsia</i> , 2009 , 50 Suppl 12, 49-50	6.4	71
145	Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. <i>CNS Drugs</i> , 2009 , 23, 555-68	6.7	55
144	Lacosamide. <i>Nature Reviews Drug Discovery</i> , 2008 , 7, 973-4	64.1	84
143	The treatment of the first seizure: the risks. <i>Epilepsia</i> , 2008 , 49 Suppl 1, 29-34	6.4	6
142	Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i> , 2008 , 49, 1239-76	6.4	703
141	Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. <i>Epilepsia</i> , 2008 , 49, 1123-41	6.4	186
140	Designing clinical trials to assess antiepileptic drugs as monotherapy : difficulties and solutions. <i>CNS Drugs</i> , 2008 , 22, 917-38	6.7	24
139	Pregabalin for the management of partial epilepsy. <i>Neuropsychiatric Disease and Treatment</i> , 2008 , 4, 1211-24	3.1	22
138	Antiepileptic drugs and brain maturation: fetal exposure to lamotrigine generates cortical malformations in rats. <i>Epilepsy Research</i> , 2008 , 78, 131-9	3	35
137	Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 544-7	3.2	22

136	Stereoselective determination of vigabatrin enantiomers in human plasma by high performance liquid chromatography using UV detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 854, 63-7	3.2	14
135	Idiosyncratic adverse reactions to antiepileptic drugs. <i>Epilepsia</i> , 2007 , 48, 1223-44	6.4	272
134	Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. <i>Epilepsia</i> , 2007 , 48, 684-93	6.4	100
133	An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. <i>Epilepsia</i> , 2007 , 48, 1292-302	6.4	166
132	Development of new antiepileptic drugs: challenges, incentives, and recent advances. <i>Lancet Neurology</i> , 2007 , 6, 793-804	24.1	259
131	Changes in plasma levetiracetam concentrations in pregnant women and their breastfed infants. <i>Nature Clinical Practice Neurology</i> , 2007 , 3, 538-9		3
130	Age-related changes in pharmacokinetics: predictability and assessment methods. <i>International Review of Neurobiology</i> , 2007 , 81, 183-99	4.4	19
129	Withdrawing antiepileptic drugs in seizure-free patients: what are the cognitive benefits?. <i>Nature Clinical Practice Neurology</i> , 2007 , 3, 194-5		1
128	A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbamazepine in human plasma. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 319-24	3.2	17
127	Old versus new antiepileptic drugs: the SANAD study. <i>Lancet</i> , 2007 , 370, 313; author reply 315-6	40	17
126	Prenatal exposure to antiepileptic drugs. <i>Lancet</i> , 2006 , 367, 1467-9	40	12
125	Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 351-63	6.2	93
124	ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. <i>Epilepsia</i> , 2006 , 47, 1094-120	6.4	603
123	Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. <i>Epilepsia</i> , 2006 , 47, 1569-72	6.4	46
122	Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. <i>Epilepsia</i> , 2006 , 47 Suppl 5, 16-20	6.4	65
121	Clinically relevant drug interactions with antiepileptic drugs. <i>British Journal of Clinical Pharmacology</i> , 2006 , 61, 246-55	3.8	420
120	Active control trials: endpoints beyond conventional efficacy and tolerability measures. <i>Epilepsy Research</i> , 2006 , 68, 73-4	3	3
119	The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data. <i>Epilepsy Research</i> , 2006 , 70, 153-60	3	23

118	Pregabalin as Adjunctive Treatment of Partial Seizures. <i>CNS Drugs</i> , 2005 , 19, 273-274	6.7	2
117	Overtreatment in epilepsy: how it occurs and how it can be avoided. <i>CNS Drugs</i> , 2005 , 19, 897-908	6.7	48
116	Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 407-16	6.2	46
115	Pharmacokinetic variability of new antiepileptic drugs at different ages. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 714-7	3.2	32
114	Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. <i>Epilepsy Research</i> , 2005 , 64, 1-11	3	55
113	An introduction to antiepileptic drugs. <i>Epilepsia</i> , 2005 , 46 Suppl 4, 31-7	6.4	100
112	Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. <i>Epilepsia</i> , 2005 , 46, 378-84	6.4	50
111	Birth defects after prenatal exposure to antiepileptic drugs. <i>Lancet Neurology, The</i> , 2005 , 4, 781-6	24.1	141
110	Predictability of metabolic antiepileptic drug interactions 2005 , 57-92		5
109	Can drug resistance in epilepsy be minimized? Challenging commonly held beliefs. <i>Epileptic Disorders</i> , 2005 , 7 Suppl 1, S14-21	1.9	1
108	Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. <i>Epilepsia</i> , 2004 , 45, 1171-5	6.4	78
107	Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. <i>Epilepsy Research</i> , 2004 , 59, 155-65	3	29
106	Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. <i>Therapeutic Drug Monitoring</i> , 2003 , 25, 54-60	3.2	23
105	Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. <i>Therapeutic Drug Monitoring</i> , 2003 , 25, 700-8	3.2	35
104	Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. <i>Lancet Neurology, The</i> , 2003 , 2, 347-56	24.1	321
103	Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. <i>Lancet Neurology, The</i> , 2003 , 2, 473-81	24.1	302
102	Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. <i>Epilepsy Research</i> , 2003 , 57, 1-13	3	114
101	Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. <i>Epilepsia</i> , 2003 , 44, 40-5	6.4	21

100	Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. <i>Epilepsia</i> , 2003 , 44, 923-9	6.4	46
99	Current trends in antiepileptic drug therapy. <i>Epilepsia</i> , 2003 , 44 Suppl 4, 41-7	6.4	18
98	Translating monotherapy trials into clinical practice: a look into the abyss. <i>Epilepsy and Behavior</i> , 2003 , 4, 457-63	3.2	9
97	The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?. <i>Epileptic Disorders</i> , 2003 , 5 Suppl 1, S17-26	1.9	9
96	Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. <i>Epilepsia</i> , 2002 , 43 Suppl 2, 37-44	6.4	91
95	Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. <i>Epilepsia</i> , 2002 , 43, 175-82	6.4	92
94	Overtreatment in epilepsy: adverse consequences and mechanisms. <i>Epilepsy Research</i> , 2002 , 52, 25-33	3	46
93	What can we learn from clinical trials of anticonvulsant drugs in epilepsy?. <i>European Journal of Pain</i> , 2002 , 6 Suppl A, 35-44	3.7	11
92	Marketed new antiepileptic drugs: are they better than old-generation agents?. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 74-80	3.2	46
91	Principles of pharmacotherapy of the epilepsies 2002 , 1301-1312		2
90	Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. <i>CNS Drugs</i> , 2002 , 16, 695-714	6.7	454
89	Patient-tailored antiepileptic drug therapy: predicting response to antiepileptic drugs. <i>International Congress Series</i> , 2002 , 1244, 93-103		4
88	Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. <i>Psychopharmacology</i> , 2001 , 153, 238-43	4.7	101
87	Trial duration and follow-up. <i>Epilepsy Research</i> , 2001 , 45, 123-7; discussion 129-31	3	3
86	Trials in the elderly. <i>Epilepsy Research</i> , 2001 , 45, 149-51; discussion 153-4	3	9
85	The management of refractory idiopathic epilepsies. <i>Epilepsia</i> , 2001 , 42 Suppl 3, 31-5	6.4	34
84	Recent advances in the diagnosis and treatment of epilepsy. <i>European Journal of Neurology</i> , 2001 , 8, 519-39	6	17
83	Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation. <i>CNS Drugs</i> , 2001 , 15, 609-21	6.7	66

82	Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication. <i>Therapeutic Drug Monitoring</i> , 2001 , 23, 217-22	3.2	30
81	Assessing risk to benefit ratio in antiepileptic drug therapy. <i>Epilepsy Research</i> , 2000 , 41, 107-39	3	92
80	The new antiepileptic drugs: pharmacological and clinical aspects. <i>Current Pharmaceutical Design</i> , 2000 , 6, 839-60	3.3	44
79	Is there a role for therapeutic drug monitoring of new anticonvulsants?. <i>Clinical Pharmacokinetics</i> , 2000 , 38, 191-204	6.2	113
78	Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. <i>Epilepsy Research</i> , 1999 , 33, 247-62	3	52
77	Enantioselective pharmacokinetics of 10-hydroxycarbamazepine after oral administration of oxcarbazepine to healthy Chinese subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 66, 547-53	6.1	60
76	The clinical pharmacokinetics of the new antiepileptic drugs. <i>Epilepsia</i> , 1999 , 40 Suppl 9, S7-13	6.4	78
75	Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. <i>Epilepsia</i> , 1998 , 39, 27-32	6.4	82
74	Pharmacoresistance in Epilepsy. <i>CNS Drugs</i> , 1998 , 10, 171-179	6.7	66
73	A pharmacological and clinical review on topiramate, a new antiepileptic drug. <i>Pharmacological Research</i> , 1997 , 35, 241-56	10.2	128
72	Pharmacologic Advantages of Antiepileptic Drug Monotherapy. <i>Epilepsia</i> , 1997 , 38, S6-S8	6.4	159
71	Evaluation of drug treatment outcome in epilepsy: a clinical perspective. <i>International Journal of Clinical Pharmacy</i> , 1997 , 19, 217-22		13
70	Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 61, 442-9	6.1	36
69	The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. <i>Clinical Pharmacokinetics</i> , 1996 , 31, 29-46	6.2	107
68	Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. <i>Clinical Pharmacokinetics</i> , 1996 , 31, 198-214	6.2	236
67	Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. <i>Epilepsia</i> , 1996 , 37 Suppl 2, S8-S13	6.4	32
66	The new generation of antiepileptic drugs: advantages and disadvantages. <i>British Journal of Clinical Pharmacology</i> , 1996 , 42, 531-43	3.8	100
65	The new generation of antiepileptic drugs: advantages and disadvantages. <i>British Journal of Clinical Pharmacology</i> , 1996 , 42, 531-543	3.8	130

64	The management of epilepsy in the 1990s. Acquisitions, uncertainties and priorities for future research. <i>Drugs</i> , 1995 , 49, 680-94	12.1	51
63	Clinical pharmacokinetics of fluvoxamine. <i>Clinical Pharmacokinetics</i> , 1994 , 27, 175-90	6.2	56
62	Newer and Older Antidepressants. <i>CNS Drugs</i> , 1994 , 2, 479-497	6.7	16
61	Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 471-6	6.1	82
60	Quantitative comparison of barbiturates in essential hand and head tremor. <i>Movement Disorders</i> , 1991 , 6, 65-8	7	32
59	Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs 1987 , 33, 139-44		49
58	Drug metabolism in pregnancy, infancy and childhood 1987 , 34, 129-43		42
57	Free and total serum concentrations of carbamazepine and carbamazepine-10,11-epoxide in infancy and childhood. <i>Epilepsia</i> , 1985 , 26, 320-2	6.4	19
56	Interpretation of drug levels in acute and chronic disease states. <i>Clinical Pharmacokinetics</i> , 1985 , 10, 498-513	6.2	27
55	Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication. <i>Clinical Pharmacokinetics</i> , 1985 , 10, 524-31	6.2	24
54	In vivo plasma protein binding interaction between valproic acid and naproxen. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1984 , 9, 359-63	2.7	11
53	Diurnal Fluctuations in Free and Total Plasma Concentrations of Carbamazepine at Steady-State and Correlation with Intermittent Side Effects in Epileptic Patients. <i>Clinical Pharmacokinetics</i> , 1984 , 9, 93-94	6.2	1
52	Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. <i>Epilepsia</i> , 1984 , 25, 476-81	6.4	74
51	Free fraction of valproic acid: in vitro time-dependent increase and correlation with free fatty acid concentration in human plasma and serum. <i>Epilepsia</i> , 1983 , 24, 65-73	6.4	90
50	Pharmacokinetic interactions with antiepileptic drugs. <i>Clinical Pharmacokinetics</i> , 1982 , 7, 57-84	6.2	68
49	Plasma protein binding of drugs in pregnancy. <i>Clinical Pharmacokinetics</i> , 1982 , 7, 336-52	6.2	104
48	Drug interactions with phenytoin. <i>Drugs</i> , 1981 , 21, 120-37	12.1	30
47	Plasma Protein Binding of Phenytoin in Health and Disease. <i>Therapeutic Drug Monitoring</i> , 1980 , 2, 331-342		46

46	Drug interactions in epilepsy. <i>Arquivos De Neuro-Psiquiatria</i> , 1980 , 38, 331-40	1.6
45	Interpretation of drug levels: relevance of plasma protein binding. <i>Novartis Foundation Symposium</i> , 1979 , 51-68	4
44	Brivaracetam447-457	6
43	Management of Side-Effects of Antiepileptic Drugs289-299	2
42	Reproductive Aspects of Epilepsy Treatment323-333	0
41	Management of Epilepsy in People with Learning Disabilities219-229	1
40	General Principles of Medical Management119-139	1
39	Management of Chronic Active Epilepsy in Adults153-162	1
38	Management of Epilepsy in Infants171-178	0
37	Management of Childhood Epilepsy Syndromes179-194	1
36	Emergency Treatment of Seizures and Status Epilepticus231-247	0
35	Mechanisms of Epileptogenesis67-79	2
34	Management of Newly Diagnosed Epilepsy141-151	1
33	Management of Epilepsy in Remission163-169	0
32	Management of Epilepsies Associated with Specific Diseases in Children195-201	1
31	Management of Epilepsy in the Elderly203-217	0
30	Management of Medical Co-morbidity Associated with Epilepsy259-272	0
29	Psychiatric Features of Epilepsy and their Management273-287	3

28	Ketogenic Diets301-310	0
27	Non-pharmacological, Complementary and Alternative Treatments for Epilepsy311-322	0
26	Epilepsy Counselling335-340	0
25	Genetic Counselling in Epilepsy341-360	0
24	Carisbamate475-484	0
23	Felbamate511-518	1
22	Introduction to the Choice of Antiepileptic Drugs365-375	2
21	Traumatic Brain Injury and Other Risks249-257	1
20	Epidemiology and Prognosis of Epilepsy21-31	3
19	Medical Treatment of Epilepsy in Situations with Limited Resources379-385	1
18	Aetiology of Epilepsy33-53	2
17	Introduction to the Choice of Antiepileptic Drugs387-398	1
16	Adrenocorticotrophic Hormone and Corticosteroids411-419	1
15	Benzodiazepines used Primarily for Emergency Treatment (Diazepam, Lorazepam and Midazolam)431-446	2
14	Eslicarbazepine Acetate485-498	29
13	Ethosuximide499-509	2
12	Differential Diagnosis of Epilepsy55-66	1
11	Phenobarbital, Primidone and Other Barbiturates585-603	3

10	Retigabine637-646	3
9	Rufinamide647-655	4
8	Antiepileptic Drug Discovery81-89	1
7	Invasive EEG in Presurgical Evaluation of Epilepsy767-798	13
6	MRI in the Presurgical Evaluation805-820	2
5	Experimental Neurophysiological Techniques829-849	1
4	Neuropsychological Testing in Presurgical Evaluation851-863	1
3	Mechanisms of Antiepileptic Drug Action91-108	3
2	Mechanisms of Tolerance and Drug Resistance109-118	23
1	Vagal Nerve Stimulation1017-1023	2